Logo image of ILMN

ILLUMINA INC (ILMN) Stock Fundamental Analysis

NASDAQ:ILMN - Nasdaq - US4523271090 - Common Stock - Currency: USD

94.79  +0.63 (+0.67%)

After market: 93.1659 -1.62 (-1.71%)

Fundamental Rating

5

Overall ILMN gets a fundamental rating of 5 out of 10. We evaluated ILMN against 55 industry peers in the Life Sciences Tools & Services industry. ILMN has an average financial health and profitability rating. ILMN has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year ILMN was profitable.
In the past year ILMN had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: ILMN reported negative net income in multiple years.
Each year in the past 5 years ILMN had a positive operating cash flow.
ILMN Yearly Net Income VS EBIT VS OCF VS FCFILMN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B -2B -3B -4B

1.2 Ratios

ILMN has a Return On Assets (-15.61%) which is in line with its industry peers.
ILMN has a worse Return On Equity (-40.75%) than 65.45% of its industry peers.
The Return On Invested Capital of ILMN (15.23%) is better than 89.09% of its industry peers.
Industry RankSector Rank
ROA -15.61%
ROE -40.75%
ROIC 15.23%
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
ILMN Yearly ROA, ROE, ROICILMN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

1.3 Margins

ILMN has a Operating Margin of 21.07%. This is amongst the best in the industry. ILMN outperforms 87.27% of its industry peers.
In the last couple of years the Operating Margin of ILMN has declined.
Looking at the Gross Margin, with a value of 66.34%, ILMN belongs to the top of the industry, outperforming 92.73% of the companies in the same industry.
In the last couple of years the Gross Margin of ILMN has remained more or less at the same level.
Industry RankSector Rank
OM 21.07%
PM (TTM) N/A
GM 66.34%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
ILMN Yearly Profit, Operating, Gross MarginsILMN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ILMN is still creating some value.
ILMN has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, ILMN has more shares outstanding
Compared to 1 year ago, ILMN has a worse debt to assets ratio.
ILMN Yearly Shares OutstandingILMN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ILMN Yearly Total Debt VS Total AssetsILMN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

ILMN has an Altman-Z score of 3.54. This indicates that ILMN is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.54, ILMN is in the better half of the industry, outperforming 74.55% of the companies in the same industry.
The Debt to FCF ratio of ILMN is 2.27, which is a good value as it means it would take ILMN, 2.27 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of ILMN (2.27) is better than 85.45% of its industry peers.
A Debt/Equity ratio of 0.63 indicates that ILMN is somewhat dependend on debt financing.
ILMN has a worse Debt to Equity ratio (0.63) than 67.27% of its industry peers.
Even though the debt/equity ratio score it not favorable for ILMN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 2.27
Altman-Z 3.54
ROIC/WACC1.53
WACC9.93%
ILMN Yearly LT Debt VS Equity VS FCFILMN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B 10B

2.3 Liquidity

ILMN has a Current Ratio of 1.86. This is a normal value and indicates that ILMN is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.86, ILMN is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
A Quick Ratio of 1.48 indicates that ILMN should not have too much problems paying its short term obligations.
ILMN's Quick ratio of 1.48 is on the low side compared to the rest of the industry. ILMN is outperformed by 61.82% of its industry peers.
Industry RankSector Rank
Current Ratio 1.86
Quick Ratio 1.48
ILMN Yearly Current Assets VS Current LiabilitesILMN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

5

3. Growth

3.1 Past

ILMN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 278.41%, which is quite impressive.
Measured over the past years, ILMN shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -17.93% on average per year.
The Revenue has decreased by -3.47% in the past year.
ILMN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.29% yearly.
EPS 1Y (TTM)278.41%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%977.78%
Revenue 1Y (TTM)-3.47%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%-3.25%

3.2 Future

ILMN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.99% yearly.
Based on estimates for the next years, ILMN will show a small growth in Revenue. The Revenue will grow by 3.86% on average per year.
EPS Next Y76.08%
EPS Next 2Y39.37%
EPS Next 3Y30.46%
EPS Next 5Y21.99%
Revenue Next Year-2.13%
Revenue Next 2Y0.45%
Revenue Next 3Y2.3%
Revenue Next 5Y3.86%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ILMN Yearly Revenue VS EstimatesILMN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B
ILMN Yearly EPS VS EstimatesILMN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6 8 10

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

ILMN is valuated quite expensively with a Price/Earnings ratio of 28.47.
ILMN's Price/Earnings ratio is a bit cheaper when compared to the industry. ILMN is cheaper than 69.09% of the companies in the same industry.
When comparing the Price/Earnings ratio of ILMN to the average of the S&P500 Index (26.98), we can say ILMN is valued inline with the index average.
The Price/Forward Earnings ratio is 19.92, which indicates a rather expensive current valuation of ILMN.
Based on the Price/Forward Earnings ratio, ILMN is valued a bit cheaper than 78.18% of the companies in the same industry.
ILMN is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.49, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 28.47
Fwd PE 19.92
ILMN Price Earnings VS Forward Price EarningsILMN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ILMN is valued cheaper than 89.09% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ILMN is valued cheaply inside the industry as 85.45% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 17.13
EV/EBITDA 12.72
ILMN Per share dataILMN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ILMN's earnings are expected to grow with 30.46% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.37
PEG (5Y)N/A
EPS Next 2Y39.37%
EPS Next 3Y30.46%

More info and screens

0

5. Dividend

5.1 Amount

ILMN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ILLUMINA INC

NASDAQ:ILMN (6/27/2025, 8:22:56 PM)

After market: 93.1659 -1.62 (-1.71%)

94.79

+0.63 (+0.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners107.23%
Inst Owner Change0.04%
Ins Owners0.17%
Ins Owner Change6.72%
Market Cap15.01B
Analysts74
Price Target110.17 (16.23%)
Short Float %3.47%
Short Ratio2.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.22%
Min EPS beat(2)-7.76%
Max EPS beat(2)1.33%
EPS beat(4)2
Avg EPS beat(4)-10.12%
Min EPS beat(4)-60.91%
Max EPS beat(4)26.88%
EPS beat(8)6
Avg EPS beat(8)314.25%
EPS beat(12)9
Avg EPS beat(12)229.49%
EPS beat(16)13
Avg EPS beat(16)180.02%
Revenue beat(2)0
Avg Revenue beat(2)-0.57%
Min Revenue beat(2)-0.95%
Max Revenue beat(2)-0.18%
Revenue beat(4)1
Avg Revenue beat(4)-0.53%
Min Revenue beat(4)-1.91%
Max Revenue beat(4)0.91%
Revenue beat(8)3
Avg Revenue beat(8)-0.59%
Revenue beat(12)4
Avg Revenue beat(12)-1.16%
Revenue beat(16)7
Avg Revenue beat(16)0.05%
PT rev (1m)-5.38%
PT rev (3m)-17.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.95%
EPS NY rev (1m)-0.31%
EPS NY rev (3m)-6.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.65%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)-2.75%
Valuation
Industry RankSector Rank
PE 28.47
Fwd PE 19.92
P/S 3.46
P/FCF 17.13
P/OCF 15.01
P/B 6.34
P/tB 15.36
EV/EBITDA 12.72
EPS(TTM)3.33
EY3.51%
EPS(NY)4.76
Fwd EY5.02%
FCF(TTM)5.53
FCFY5.84%
OCF(TTM)6.32
OCFY6.66%
SpS27.4
BVpS14.96
TBVpS6.17
PEG (NY)0.37
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.61%
ROE -40.75%
ROCE 19.27%
ROIC 15.23%
ROICexc 20.6%
ROICexgc 34.16%
OM 21.07%
PM (TTM) N/A
GM 66.34%
FCFM 20.2%
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-6.48%
ROICexc growth 3YN/A
ROICexc growth 5Y-9.28%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
F-Score6
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 2.27
Debt/EBITDA 1.21
Cap/Depr 39.37%
Cap/Sales 2.86%
Interest Coverage 250
Cash Conversion 81.37%
Profit Quality N/A
Current Ratio 1.86
Quick Ratio 1.48
Altman-Z 3.54
F-Score6
WACC9.93%
ROIC/WACC1.53
Cap/Depr(3y)66.6%
Cap/Depr(5y)76.75%
Cap/Sales(3y)5.82%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)278.41%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%977.78%
EPS Next Y76.08%
EPS Next 2Y39.37%
EPS Next 3Y30.46%
EPS Next 5Y21.99%
Revenue 1Y (TTM)-3.47%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%-3.25%
Revenue Next Year-2.13%
Revenue Next 2Y0.45%
Revenue Next 3Y2.3%
Revenue Next 5Y3.86%
EBIT growth 1Y1675.86%
EBIT growth 3YN/A
EBIT growth 5Y-7.67%
EBIT Next Year26.49%
EBIT Next 3Y15.01%
EBIT Next 5Y12.66%
FCF growth 1Y484.21%
FCF growth 3Y28.14%
FCF growth 5Y-3.38%
OCF growth 1Y334.78%
OCF growth 3Y15.37%
OCF growth 5Y-4.45%